Exhibit 99.1
Cytori Provides Twelve Month Data Update on Scleradec-I Trial
April 13, 2015
SAN DIEGO — Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today preliminary 12 month follow-up data from the 12 patient investigator initiated Scleradec-I clinical trial conducted by Prof. B. Granel and Prof. G. Magalon from the Assistance Publique des Hôpitaux de Marseille.
In the previously published six month follow-up data, Cytori’s ECCS-50 therapeutic showed:
| | • | | Improvement in Cochin Hand Function Scale (CHFS) from mean of 48.5 at baseline to 21.2 at six months |
| | • | | Improvement in Hand Pain (Visual Analog Scale) from mean of 59.4 at baseline to 17.8 at six months |
| | • | | Improvement in Raynaud’s Condition Score (RCS) from mean of 7.2 at baseline to 2.9 at six months |
| | • | | Improvement in Scleroderma Health Assessment Questionnaire (SHAQ) score from mean of 1.4 at baseline to 0.8 at six months |
The manuscript describing these data in detail can be viewed athttp://ard.bmj.com/content/early/2014/08/10/annrheumdis-2014-205681.long.
A preliminary assessment for 12 month follow-up data has been reviewed by the Company which management believes reflects:
| | • | | No reports of adverse events or safety concerns |
| | • | | Average values for CHFS, RCS, and SHAQ score are statistically consistent with those at the 6 month follow up visit |
| | • | | While the average hand pain at 12 months was lower than that at baseline (reflecting overall symptom improvement over baseline), there was an approximately 50% reduction in the average therapeutic benefit on hand pain from six to twelve months |
The investigators have prepared and submitted for publication a scientific manuscript based on final 12 month data. Once this manuscript has been accepted for publication and a publication date announced, Cytori will provide an update to investors.
About Cytori Therapeutics, Inc.
Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information: visit www.cytori.com.
Cytori Therapeutics, Inc.
Shawn Richardson, 1.858.875.5279
ir@cytori.com
